Recombinant Human ALK-2 (C-Fc)-Target Proteins-EnkiLife-Recombinant Proteins,Antibodies,Kits,Cell Biology

Name	Recombinant Human ALK-2 (C-Fc)
Purity	Greater than 95% as determined by reducing SDS-PAGE
Endotoxin level	<1 EU/µg as determined by LAL test.
Construction	Recombinant Human Receptor Protein Serine/Threonine Kinase is produced by our Mammalian expression system and the target gene encoding Asp23/xadVal124 is expressed with a human IgG1 Fc tag at the C-terminus.
Accession #	Q53SV1
Host	Human Cells
Species	Human
Predicted Molecular Mass	38.2 KDa
Buffer	Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
Form	Lyophilized
Shipping	The product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.
Stability&Storage	Store at ≤-70°C, stable for 6 months after receipt.Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
Reconstitution	Always centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

Alternative Names

activin A receptor, type I; Activin RIA; ActivinRIA; ACTRI; ACVR1; ACVR1A; ACVRLK2; ALK2; ALK-2; FOP; SKR1; TSRI

Background

Activin RIA, also known as ALK-2, TSK-7L, SKR1, TSR-I, and ACTR-I, is a glycosylated 65 kDa type I receptor in the TGF-beta serine/threonine kinase receptor family. Binding of TGF-beta superfamily ligands induces formation of a heterotetrameric complex that contains two chains each of a type I and a type II receptor in multiple combinations. The type II receptors phosphorylate the type I receptors which then phosphorylate and activate Smad signal transduction proteins. Activin RIA functions in a wide variety of growth and differentiation processes including gastrulation, skeletal system development, and cardiac morphogenesis. BMP signaling through Activin RIA is enhanced by the direct interaction between Activin RIA and RGM-B/DRAGON, a BMP coreceptor that also associates with other type I and type II receptors. Activin RIA can additionally phosphorylate the coreceptor Endoglin and is required for the inhibitory effect of Endoglin on prostate cancer cell motility.

Note

For Research Use Only , Not for Diagnostic Use.